Program 29 September 2022

Wonderful class and very interesting presentations! Quote Masterclass AMR 2021

General introductions by Dr Maarten van Dongen. International experts provide their up-to-date, specialist views on different topics followed by short interviews. Ample room for Q&A during the sessions.

Times indicated in Central European Summer Time (CEST).

09:30	Welcome and introduction to Antimicrobial resistance (AMR) Dr Maarten van Dongen; AMR Insights (Netherlands)
	A closer acquaintance to and demarcation of AMR. How AMR is viewed from different sectors and how we communicate about AMR. How to acknowledge AMR adequately.
10:00	Bacteria: desperately needed and detested Dr Maarten van Dongen; Dr Marjolein Klaassen, Massachusetts General Hospital/MIT/Harvard University, Boston MA (USA)
	What are bacteria, where they occur and how they multiply and spread. What types and subtypes are there and which ones are harmful or pathogenic. What function do bacteria have, what diseases in humans, animals and plants can they cause and why we also desperately need bacteria. What is the ‘Microbiome’ and what role does it play?
10:30	Antibiotics: desperately needed but also cause of AMR Expert: Dr Rohini Wadanamby; Lanka hospital, Colombo (Sri Lanka)
	What are antibiotics. How they were discovered and how they work. What (classes of) antibiotics there are and how they protect us. And how do they differ. Why and when to use antibiotics and how to appropriately use these in a cost effective way. And when not to use..
11:15	Antibiotic & antimicrobial resistance: the overall picture Dr Maarten van Dongen, AMR Insights (Netherlands)
	What are antibiotic resistance and Antimicrobial resistance (AMR). How these develop and spread around the world. Why AMR is increasingly threatening our health and food safety: statistics, socio-economic implications and consequences for public human and animal health. The real impact of AMR and the implications of the ‘visible’ corona pandemic for the ‘hidden’ AMR pandemic. The worldwide increase of a phenomenon that we cannot yet control.
12:00	AMR cases and patient stories Selected participants to share their personal experiences and patient stories
	Reflection on the morning program, Q&A, AMR cases and experiences by participants.
12:30	Break
	Lunch possibility
13:00	The global strategy to combat AMR Dr Maarten van Dongen, AMR Insights
	The WHO Global Action Plan and how National Action Plans add to the curbing AMR. How WHO, FAO, UNEP and WOAH join forces. The UN and other organisations involved to monitor and control AMR. An overview of the global stakeholders.
13:30	6 Key strategies to tackle AMR in the One Health perspective Dr Maarten van Dongen, AMR Insights
	The 6 important, key strategies in the One Health perspective to stop the global escalation of AMR. The ‘why, how and what’ of the different strategies, how they reinforce each other and add to an effective, global control of AMR. The global challenges related to the individual strategies.
13:45	The novel diagnostics perspective: how private companies add to tackling AMR Experts Dr Juliette van den Dolder; NYtor (Netherlands) and Dr Laureen Ferchaud; Molzym (Germany)
	SMEs face the challenge of translating high-quality technology from university research and from their own research into market-oriented applications. And thus contribute to the fight against AMR. Two experts discuss what this means. Final text follows.
14:15	The novel antibiotics perspective: how private companies add to tackling AMR Expert: Dr Sébastien Coyne, Evotec (France)
	The presentation ‘Alternative approach to discover small molecule antibiotics’ puts in a broader perspective the challenges related to antibiotics R&D.
14:30	Strategy 1: Antibiotic Stewardship and knowledge sharing as a force for tackling AMR Expert: Prof Dilip Nathwani; Honorary Emeritus Professor of Infection, University of Dundee (UK)
	Monitoring and limiting the use of antibiotics reduces the risk of AMR. How this can be implemented in human and animal health care: feasibility in HIC and LMICs alike. The potential of stewardship to diminish AMR, the relevance of knowledge sharing and the role of the newly set up GASPh. The recent launch of the BSAC Global Antimicrobial Stewardship Accreditation Scheme (GAMSAS).
15:00	Strategy 2: Microbial Diagnostics and new technologies to reach the market Expert: Prof Till Bachmann; University of Edinburgh, Edinburgh (UK)
	Diagnostics help us to set the proper patient treatment. Diagnostics distinguish bacteria from viruses, identify bacterial species (ID) and determine the antibiotics sensitivity (AST). Do we use diagnostics properly and do we use the proper diagnostics. Emerging scientific developments in diagnostics and what new diagnostic tools may reach the market.
15:30	Strategy 3: Novel Antibiotics and the context of the broken market Expert: Usha Lamichhane; Global AMR R&D Hub (Germany)
	New antibiotics, to which bacteria are still sensitive, are increasingly needed in the global fight against AMR. Why only very few new antibiotics appear on the market. Challenges related to antimicrobial R&D, the lack of funding and a proper return of investment for pharma companies. Upcoming market push and market pull mechanisms in the UK and the USA. The important roles played by CARB-X, GARDP, AMR Industry Alliance and AMR Action Fund. This all in the perspective of the Global AMR R&D Hub.
16:00	Strategy 4: Infection Prevention and Control and the key role of vaccination Expert: Prof Cal MacLennan; Professor of Vaccine Immunology at the University of Birmingham (UK)
	Infection prevention results in the decreased use of antibiotics and prevents (resistant) bacteria from spreading. The impact of vaccination of humans and animals (in addition to good sanitation, hygiene and use of disinfectants) to prevent AMR. The impact of the global bacterial vaccinology network BactiVac to accelerate the development of vaccines relevant to LMICs.
16:30	Strategy 5: Alternative Antimicrobials such as phage therapy ^{Expert: Prof Jayaseelan Murugaiyan; SRM University AP (India)}
	Alternatives to antibiotics are increasingly important to curb AMR. In addition to phage therapy, antimicrobial tissue replacers, nanomaterials and probiotics appear to fight (resistant) bacteria without leading to AMR. What are the developments and what are the promises in theory and practice. A unique, structured overview of all alternatives and where they can be used.
17:00	Strategy 6: Reducing Antibiotic Emissions in waste water Expert: Dale Stemple, Viatris (Head Global EHS – NA/Europe and China)/ AMR Industry Alliance (Switzerland)
	The environmental dimensions of AMR are recognized as part of the “One Health” approach to addressing AMR. Antibiotics that enter the aquatic environment, eg from animal and human use and excretion, from antibiotic manufacturing waste water, may present a risk of resistance developing in environmental bacteria unless adequately controlled. In this session The AMR Industry Alliance will describe its work with the British Standards Institution to develop antibiotic manufacturing standard (establishing adequate control) and an accompanying and currently under development certification scheme that will provide independent verification that an antibiotic is made in accordance with the standard. Includes intro Dutch Consortium Antibiotics and Pharmaceutical Residues from Water & White Paper by Tom Vereijken* (EWS)*
17:30	Closure

Thanks to all the panellists! Such an inspiring masterclass
Quote Masterclass AMR 2021